Clinical Trial Update: Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic Study of GSK2881078 and Study to Evaluate the Effect of CYP3A4 Inhibition on PK of GSK2881078 [Phase 1]

View source ↗

Summary

This Phase 1 study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of GSK2881078 and investigated the impact of CYP3A4 inhibition on its …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cachexia

Drugs mentioned

• GSK2881078 (GSK2881078)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cachexia | Phase 1 | Status: COMPLETED